Zevra Therapeutics Statistics
Share Statistics
Zevra Therapeutics has 53.38M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 53.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 6 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.94M, so 7.38% of the outstanding shares have been sold short.
| Short Interest | 3.94M |
| Short % of Shares Out | 7.38% |
| Short % of Float | 7.44% |
| Short Ratio (days to cover) | 5.31 |
Valuation Ratios
The PE ratio is -5.04 and the forward PE ratio is -22.08.
| PE Ratio | -5.04 |
| Forward PE | -22.08 |
| PS Ratio | 8.46 |
| Forward PS | 5.1 |
| PB Ratio | 3.75 |
| P/FCF Ratio | -6.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Zevra Therapeutics Inc. has an Enterprise Value (EV) of 232.93M.
| EV / Earnings | -5.06 |
| EV / Sales | 8.48 |
| EV / EBITDA | -4.79 |
| EV / EBIT | -4.7 |
| EV / FCF | -6.89 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.18 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.69 |
| Total Debt / Capitalization | 40.87 |
| Cash Flow / Debt | -0.78 |
| Interest Coverage | -33.05 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on capital (ROIC) is -46.96%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -46.96% |
| Revenue Per Employee | 422.48K |
| Profits Per Employee | -708.45K |
| Employee Count | 65 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.12 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 77.94% in the last 52 weeks. The beta is 1.93, so Zevra Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | 77.94% |
| 50-Day Moving Average | 8.64 |
| 200-Day Moving Average | 6.54 |
| Relative Strength Index (RSI) | 41.93 |
| Average Volume (20 Days) | 845.53K |
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of $27.46M and earned -$46.05M in profits. Earnings per share was $-1.3.
| Revenue | 27.46M |
| Gross Profit | 24.52M |
| Operating Income | -49.60M |
| Net Income | -46.05M |
| EBITDA | -48.60M |
| EBIT | -49.60M |
| Earnings Per Share (EPS) | -1.3 |
Balance Sheet
The company has $43.05M in cash and $43.77M in debt, giving a net cash position of -$716.00K.
| Cash & Cash Equivalents | 43.05M |
| Total Debt | 43.77M |
| Net Cash | -716.00K |
| Retained Earnings | -399.78M |
| Total Assets | 191.55M |
| Working Capital | 64.96M |
Cash Flow
In the last 12 months, operating cash flow was -$33.53M and capital expenditures -$296.00K, giving a free cash flow of -$33.83M.
| Operating Cash Flow | -33.53M |
| Capital Expenditures | -296.00K |
| Free Cash Flow | -33.83M |
| FCF Per Share | -0.95 |
Margins
Gross margin is 89.28%, with operating and profit margins of -180.63% and -167.69%.
| Gross Margin | 89.28% |
| Operating Margin | -180.63% |
| Pretax Margin | -167.69% |
| Profit Margin | -167.69% |
| EBITDA Margin | -176.97% |
| EBIT Margin | -180.63% |
| FCF Margin | -123.2% |
Dividends & Yields
ZVRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.35% |
| FCF Yield | -7.48% |
Analyst Forecast
The average price target for ZVRA is $21, which is 147.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 147.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Dec 28, 2020. It was a backward split with a ratio of 1:16.
| Last Split Date | Dec 28, 2020 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | -2.04 |
| Piotroski F-Score | 2 |